15.75
0.16 (1.03%)
Previous Close | 15.59 |
Open | 15.52 |
Volume | 1,551,042 |
Avg. Volume (3M) | 1,585,026 |
Market Cap | 1,049,063,424 |
Price / Earnings (Forward) | 1.11 |
Price / Sales | 0.760 |
Price / Book | 5.84 |
52 Weeks Range | |
Earnings Date | 6 Aug 2025 |
Profit Margin | -18.71% |
Operating Margin (TTM) | -14.71% |
Diluted EPS (TTM) | -2.79 |
Quarterly Revenue Growth (YOY) | 22.30% |
Total Debt/Equity (MRQ) | 320.75% |
Current Ratio (MRQ) | 2.30 |
Operating Cash Flow (TTM) | 13.94 M |
Levered Free Cash Flow (TTM) | 67.48 M |
Return on Assets (TTM) | -6.17% |
Return on Equity (TTM) | -92.31% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | Tandem Diabetes Care, Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | -3.5 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -0.5 |
Average | -1.50 |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Core |
% Held by Insiders | 0.95% |
% Held by Institutions | 110.87% |
Ownership
Name | Date | Shares Held |
---|---|---|
Paradice Investment Management Llc | 31 Mar 2025 | 1,649,907 |
52 Weeks Range | ||
Price Target Range | ||
High | 51.00 (Barclays, 223.81%) | Buy |
Median | 20.50 (30.16%) | |
Low | 13.00 (Wells Fargo, -17.46%) | Hold |
Average | 22.75 (44.44%) | |
Total | 3 Buy, 4 Hold, 1 Sell | |
Avg. Price @ Call | 13.13 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Barclays | 08 Aug 2025 | 51.00 (223.81%) | Buy | 11.52 |
Canaccord Genuity | 07 Aug 2025 | 24.00 (52.38%) | Buy | 11.52 |
Piper Sandler | 07 Aug 2025 | 14.00 (-11.11%) | Hold | 11.52 |
RBC Capital | 07 Aug 2025 | 25.00 (58.73%) | Buy | 11.52 |
UBS | 07 Aug 2025 | 17.00 (7.94%) | Hold | 11.52 |
Wells Fargo | 07 Aug 2025 | 13.00 (-17.46%) | Hold | 11.52 |
Citigroup | 09 Jul 2025 | 14.00 (-11.11%) | Sell | 15.85 |
22 May 2025 | 24.00 (52.38%) | Hold | 20.64 | |
Truist Securities | 16 Jun 2025 | 24.00 (52.38%) | Hold | 20.04 |
No data within this time range.
Date | Type | Details |
---|---|---|
07 Aug 2025 | Announcement | Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps |
31 Jul 2025 | Announcement | Tandem Diabetes Care Announces Upcoming Conference Participation |
15 Jul 2025 | Announcement | Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity |
01 Jul 2025 | Announcement | Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 |
20 Jun 2025 | Announcement | Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States |
10 Jun 2025 | Announcement | Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |